Multimodal Oncology Agent for IDH1 Mutation Prediction in Low-Grade Glioma

Fuente: arXiv
Saved in:
Bibliographic Details
Main Authors: Akebli, Hafsa, Shephard, Adam, Della Mea, Vincenzo, Rajpoot, Nasir
Format: Preprint
Published: 2025
Subjects:
Online Access:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1866911304591081472
author Akebli, Hafsa
Shephard, Adam
Della Mea, Vincenzo
Rajpoot, Nasir
author_facet Akebli, Hafsa
Shephard, Adam
Della Mea, Vincenzo
Rajpoot, Nasir
contents Low-grade gliomas frequently present IDH1 mutations that define clinically distinct subgroups with specific prognostic and therapeutic implications. This work introduces a Multimodal Oncology Agent (MOA) integrating a histology tool based on the TITAN foundation model for IDH1 mutation prediction in low-grade glioma, combined with reasoning over structured clinical and genomic inputs through PubMed, Google Search, and OncoKB. MOA reports were quantitatively evaluated on 488 patients from the TCGA-LGG cohort against clinical and histology baselines. MOA without the histology tool outperformed the clinical baseline, achieving an F1-score of 0.826 compared to 0.798. When fused with histology features, MOA reached the highest performance with an F1-score of 0.912, exceeding both the histology baseline at 0.894 and the fused histology-clinical baseline at 0.897. These results demonstrate that the proposed agent captures complementary mutation-relevant information enriched through external biomedical sources, enabling accurate IDH1 mutation prediction.
format Preprint
id arxiv_https___arxiv_org_abs_2512_05824
institution arXiv
publishDate 2025
record_format arxiv
spellingShingle Multimodal Oncology Agent for IDH1 Mutation Prediction in Low-Grade Glioma
Akebli, Hafsa
Shephard, Adam
Della Mea, Vincenzo
Rajpoot, Nasir
Artificial Intelligence
Computer Vision and Pattern Recognition
Low-grade gliomas frequently present IDH1 mutations that define clinically distinct subgroups with specific prognostic and therapeutic implications. This work introduces a Multimodal Oncology Agent (MOA) integrating a histology tool based on the TITAN foundation model for IDH1 mutation prediction in low-grade glioma, combined with reasoning over structured clinical and genomic inputs through PubMed, Google Search, and OncoKB. MOA reports were quantitatively evaluated on 488 patients from the TCGA-LGG cohort against clinical and histology baselines. MOA without the histology tool outperformed the clinical baseline, achieving an F1-score of 0.826 compared to 0.798. When fused with histology features, MOA reached the highest performance with an F1-score of 0.912, exceeding both the histology baseline at 0.894 and the fused histology-clinical baseline at 0.897. These results demonstrate that the proposed agent captures complementary mutation-relevant information enriched through external biomedical sources, enabling accurate IDH1 mutation prediction.
title Multimodal Oncology Agent for IDH1 Mutation Prediction in Low-Grade Glioma
topic Artificial Intelligence
Computer Vision and Pattern Recognition
url https://arxiv.org/abs/2512.05824